All In Biotech

Free tool

FAERS Monitor: Rexulti

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205422 or its brand name (Rexulti, Brexpiprazole). Reports on generic versions are filed under their own applications.

Reports

16,890

Serious

7,192

43% of reports

Hospitalization

2,240

Death reported

1,179

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • weight increased1,712
  • product use in unapproved indication1,400
  • off label use1,172
  • drug ineffective984
  • akathisia880
  • tremor662
  • anxiety629
  • death603
  • tardive dyskinesia603
  • depression598
  • suicidal ideation595
  • product use issue516
  • insomnia513
  • fatigue512
  • feeling abnormal484

Reports by year received

View as table
YearReports
20121
20131
2015229
20162,107
20171,551
20181,417
20191,701
20201,423
20211,433
20221,328
20231,446
20241,781
20251,372
20261,100

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,269 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
akathisiaSignal88085.880.268,945
tardive dyskinesiaSignal60327.225.114,873
weight increasedSignal1,7129.69.213,197
suicidal ideationSignal5958.17.53,712
product use in unapproved indicationSignal1,4007.16.77,333
tremorSignal6625.04.62,112
product use issueSignal5163.43.1889
depressionSignal5983.33.0953
anxietySignal6292.82.6710
feeling abnormalSignal4842.52.3446
insomniaSignal5132.42.2423
off label use1,1721.71.6326
drug ineffective9840.90.95
death6030.90.812
fatigue5120.80.821

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.